- Reuters
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/1/2024 | $205.00 → $245.00 | Neutral → Overweight | Piper Sandler |
| 12/4/2023 | $261.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/21/2023 | Buy → Hold | Needham | |
| 5/30/2023 | $293.00 | Buy | CL King |
| 5/30/2023 | $261.00 | Equal-Weight | Morgan Stanley |
| 4/26/2023 | Outperform → Peer Perform | Wolfe Research | |
| 10/26/2022 | $220.00 | Neutral | Mizuho |
| 10/14/2022 | $305.00 | Overweight | Stephens |
WAYNE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE:TFX), is scheduled to speak at the Jefferies London Healthcare Conference, on Thursday, November 21, 2024, at 9:30 a.m. (GMT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergenc
WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 16, 2024, to shareholders of record at the close of business on November 15, 2024. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiol
WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the third quarter ended September 29, 2024. Third quarter financial summary GAAP revenue of $764.4 million, up 2.4% compared to the prior year period, up 2.2% on a constant currency basis GAAP diluted EPS from continuing operations of $2.36, compared to $2.91 in the prior year period Adjusted diluted EPS from continuing operations of $3.49, compared to $3.64 in the prior year period 2024 guidance summary Lowering GAAP revenue growth guidance range to 2.90% to 3.40% Lowering adjusted constant currency revenue growth guidance range to 3.50% to 4.00% Rai
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4/A - TELEFLEX INC (0000096943) (Issuer)
Piper Sandler upgraded Teleflex from Neutral to Overweight and set a new price target of $245.00 from $205.00 previously
Morgan Stanley upgraded Teleflex from Equal-Weight to Overweight and set a new price target of $261.00
Needham downgraded Teleflex from Buy to Hold
10-Q - TELEFLEX INC (0000096943) (Filer)
8-K - TELEFLEX INC (0000096943) (Filer)
8-K - TELEFLEX INC (0000096943) (Filer)
ROCK HILL, S.C., May 16, 2022 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced the formation of the company's first Medical Advisory Board (MAB) and the appointment of Stephen K. Klasko, MD, MBA as Chair. The primary mission of the MAB will be to provide strategic input, guidance, and recommendations for the company's emerging regenerative medicine efforts as they begin moving from research into advanced development and, ultimately, into human application. The MAB will comprise a diverse spectrum of skill sets and experiences ranging from scientific expertise to commercial application, including advising on the formation of key partnerships to reduce program risks and accelerate
PARK CITY, Utah, Dec. 28, 2020 /PRNewswire/ -- DW Healthcare Partners ("DWHP") a healthcare-focused private equity firm, announced today the closing of its previously disclosed sale of Z-Medica ("Z-Medica" or "the Company") to Teleflex Incorporated (NYSE: TFX) ("Teleflex"). Z-Medica, a portfolio company of DW Healthcare Partners and Linden Capital Partners ("Linden"), is a leading manufacturer and marketer of patented hemostatic products that enable healthcare providers, military personnel, and first responders to control bleeding and hemorrhaging. DWHP first invested in Z-Medica in September of 2012 and realized substantial growth in the business through channel diversification and new p
Analysts' ratings for Teleflex (NYSE:TFX) over the last quarter vary from bullish to bearish, as provided by 4 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $234.75, along with a high estimate of $245.00 and a low estimate of $219.00. Surpassing the previous average price target of $2
Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:TFX) with a Hold and raises the price target from $235 to $240.
WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 16, 2024, to shareholders of record at the close of business on November 15, 2024. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiol
WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the third quarter ended September 29, 2024. Third quarter financial summary GAAP revenue of $764.4 million, up 2.4% compared to the prior year period, up 2.2% on a constant currency basis GAAP diluted EPS from continuing operations of $2.36, compared to $2.91 in the prior year period Adjusted diluted EPS from continuing operations of $3.49, compared to $3.64 in the prior year period 2024 guidance summary Lowering GAAP revenue growth guidance range to 2.90% to 3.40% Lowering adjusted constant currency revenue growth guidance range to 3.50% to 4.00% Rai
WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 31, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on October 31, 2024, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 990